Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BULLETIN
October 21, 2002
- DIAGNOSTIC NEWS IN BRIEF
October 21, 2002
- The 61st Annual Meeting of the Japanese Cancer Associarion
October 21, 2002
- 21st IFPMA Assembly Held in Berlin
October 21, 2002
- Communication Is Most Important in Int'l Collaborative Studies: Prof. Uchida
October 21, 2002
- Korosho Study Group Recommends AUTs for OTC Drugs
October 21, 2002
- OTC NEWS IN BRIEF
October 21, 2002
- ON THE MOVE
October 21, 2002
- Tanabe Stresses Enhancement of Competitiveness as Research-oriented Firm: President Hayama
October 21, 2002
- Fujisawa Introduces Atlas Data Suit from Gene Logic
October 21, 2002
- Healthcare Expenditures Down 1.6% in 2nd QTR VS 1st QTR
October 14, 2002
- REGULATORY NEWS IN BRIEF
October 14, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 14, 2002
- Physician-led Trials to Start on New Indication for Irinotecan
October 14, 2002
- Korosho Pledges to Smoothly Implement New Blood Law
October 14, 2002
- Korosho to Give Priority to Useful Drugs in Clinical Trial Consultation
October 14, 2002
- New ADR Information System under Investigation
October 14, 2002
- BUSINESS NEWS IN BRIEF
October 14, 2002
- WORLD NEWS IN BRIEF
October 14, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
October 14, 2002
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…